Cargando…

Honokiol Prevents Non-Alcoholic Steatohepatitis-Induced Liver Cancer via EGFR Degradation through the Glucocorticoid Receptor—MIG6 Axis

SIMPLE SUMMARY: Non-alcoholic fatty liver disease (NAFLD) is a major health problem globally linked with the growing prevalence of metabolic syndrome. A subset of patients with NAFLD progress to non-alcoholic steatohepatitis (NASH), which increases the risk of hepatocellular carcinoma (HCC). However...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okuda, Keiichiro, Umemura, Atsushi, Umemura, Shiori, Kataoka, Seita, Taketani, Hiroyoshi, Seko, Yuya, Nishikawa, Taichiro, Yamaguchi, Kanji, Moriguchi, Michihisa, Kanbara, Yoshihiro, Arbiser, Jack L., Shima, Toshihide, Okanoue, Takeshi, Karin, Michael, Itoh, Yoshito
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037653/ https://www.ncbi.nlm.nih.gov/pubmed/33806040 http://dx.doi.org/10.3390/cancers13071515

Ejemplares similares

Honokiol Acts as a Potent Anti-Fibrotic Agent in the Liver through Inhibition of TGF-β1/SMAD Signaling and Autophagy in Hepatic Stellate Cells
por: Kataoka, Seita, et al.
Publicado: (2021)

Enhanced Antitumor Effect in Liver Cancer by Amino Acid Depletion-Induced Oxidative Stress
por: Okuda, Keiichiro, et al.
Publicado: (2021)

Potential Therapeutic Targets and Promising Agents for Combating NAFLD
por: Umemura, Atsushi, et al.
Publicado: (2022)

Effect of Sodium Glucose Cotransporter 2 Inhibitors on Renal Function in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Japan
por: Yano, Kota, et al.
Publicado: (2020)

FIB-4 Index and Diabetes Mellitus Are Associated with Chronic Kidney Disease in Japanese Patients with Non-Alcoholic Fatty Liver Disease
por: Seko, Yuya, et al.
Publicado: (2019)

The Association between the Platelet Count and Liver Volume in Compensated Cirrhosis Patients after the Eradication of Hepatitis C virus by Direct-acting Antivirals
por: Seko, Yuya, et al.
Publicado: (2020)

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
por: Seko, Yuya, et al.
Publicado: (2018)

Tyrosine Kinase Inhibitors Stimulate HLA Class I Expression by Augmenting the IFNγ/STAT1 Signaling in Hepatocellular Carcinoma Cells
por: Takahashi, Aya, et al.
Publicado: (2021)

Comparison of portal vein hemodynamics with ultrasound-based elastography for the prediction of liver fibrosis in patients with chronic liver disease
por: Yamaguchi, Kanji, et al.
Publicado: (2023)

The Appropriate Opportunity for Evaluating Liver Fibrosis by Using the FIB-4 Index in Patients with Nonalcoholic Fatty Liver Disease in Japan
por: Seko, Yuya, et al.
Publicado: (2020)

The Effect of Genetic Polymorphism in Response to Body Weight Reduction in Japanese Patients with Nonalcoholic Fatty Liver Disease
por: Seko, Yuya, et al.
Publicado: (2021)

Aging-associated impairment in metabolic compensation by subcutaneous adipose tissue promotes diet-induced fatty liver disease in mice
por: Taketani, Hiroyoshi, et al.
Publicado: (2019)

Loss of KAP3 decreases intercellular adhesion and impairs intracellular transport of laminin in signet ring cell carcinoma of the stomach
por: Soda, Tomohiro, et al.
Publicado: (2022)

PPARα agonist and metformin co-treatment ameliorates NASH in mice induced by a choline-deficient, amino acid-defined diet with 45% fat
por: Okishio, Shinya, et al.
Publicado: (2020)

The additive effect of genetic and metabolic factors in the pathogenesis of nonalcoholic fatty liver disease
por: Seko, Yuya, et al.
Publicado: (2022)

Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions
por: Fujii, Hideki, et al.
Publicado: (2017)

Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis
por: Takahashi, Aya, et al.
Publicado: (2020)

Epidemiology, Pathogenesis, and Diagnostic Strategy of Diabetic Liver Disease in Japan
por: Sumida, Yoshio, et al.
Publicado: (2020)

Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo
por: Bonner, Michael Y., et al.
Publicado: (2016)

A Review of Non-operative Treatments for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombus
por: Moriguchi, Michihisa, et al.
Publicado: (2017)

Honokiol is a FOXM1 antagonist
por: Halasi, Marianna, et al.
Publicado: (2018)

Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan
por: Sakakida, Tomoki, et al.
Publicado: (2023)

EVI1, a target gene for amplification at 3q26, antagonizes transforming growth factor-β-mediated growth inhibition in hepatocellular carcinoma
por: Yasui, Kohichiroh, et al.
Publicado: (2015)

Pathogenic Role of Iron Deposition in Reticuloendothelial Cells during the Development of Chronic Hepatitis C
por: Mitsuyoshi, Hironori, et al.
Publicado: (2013)

Combinatorial control of gene expression by the three yeast repressors Mig1, Mig2 and Mig3
por: Westholm, Jakub Orzechowski, et al.
Publicado: (2008)

Pro-Apoptotic Activity of New Honokiol/Triphenylmethane Analogues in B-Cell Lymphoid Malignancies
por: Mędra, Aleksandra, et al.
Publicado: (2016)

Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers
por: Kawaguchi, Takahisa, et al.
Publicado: (2018)

Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial SIRT3
por: Pillai, Vinodkumar B., et al.
Publicado: (2015)

Honokiol Inhibits SARS-CoV-2 Replication in Cell Culture at a Post-Entry Step
por: Salgado-Benvindo, Clarisse, et al.
Publicado: (2023)

Honokiol activates LKB1-miR-34a axis and antagonizes the oncogenic actions of leptin in breast cancer
por: Avtanski, Dimiter B., et al.
Publicado: (2015)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
por: Zang, Hongjing, et al.
Publicado: (2020)

Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis
por: Nagalingam, Arumugam, et al.
Publicado: (2012)

Induction of STK11-dependent cytoprotective autophagy in breast cancer cells upon honokiol treatment
por: Muniraj, Nethaji, et al.
Publicado: (2020)

Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice
por: Pillai, Vinodkumar B., et al.
Publicado: (2017)

Erratum to: Honokiol activates AMP-activated protein kinase in breast cancer cells via LKB1-dependent pathway and inhibits breast carcinogenesis
por: Nagalingam, Arumugam, et al.
Publicado: (2017)

Identification of a Fatty Acid for Diagnosing Non-Alcoholic Steatohepatitis in Patients with Severe Obesity Undergoing Metabolic Surgery
por: Takahashi, Naoto, et al.
Publicado: (2022)

Mechanism of the development of nonalcoholic steatohepatitis after pancreaticoduodenectomy
por: Nagaya, Tadanobu, et al.
Publicado: (2015)

Antineoplastic Effects of Honokiol on Melanoma
por: Guillermo-Lagae, Ruth, et al.
Publicado: (2017)

The application prospects of honokiol in dermatology
por: Li, Yao, et al.
Publicado: (2022)

Evaluating glaucoma surgeries in the MIGS context
por: Dhingra, Deepika, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u3iho660udmqq26e9t0v5neisg